The US dietary supplement industry’s success could make Food and Drug Administration regulations for its products vulnerable to challenge with the Supreme Court striking the Chevron doctrine of deference, particularly a rule considered the chief impediment to further growth.
“This is an industry that has been, that has been really concerned about FDA, about this drug preclusion provision, about...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?